$4.14
-0.06 (-1.43%)
Open$4.21
Previous Close$4.20
Day High$4.25
Day Low$4.07
52W High$7.61
52W Low$3.27
Volume—
Avg Volume328.2K
Market Cap244.67M
P/E Ratio—
EPS$-0.98
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+600.2% upside
Current
$4.14
$4.14
Target
$28.99
$28.99
$18.54
$28.99 avg
$38.99
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 28.59M | 24.41M | 271.86M |
| Net Income | -68,710,789 | -52,791,284 | 13.33M |
| Profit Margin | -240.3% | -228.3% | 4.9% |
| EBITDA | -76,825,595 | -62,305,203 | 20.13M |
| Free Cash Flow | — | — | 11.27M |
| Rev Growth | +17.1% | +17.1% | -6.6% |
| Debt/Equity | — | — | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |